Univariable logistic regression analysis of predictors for CM-TMA recurrence after eculizumab discontinuation
| . | Odds ratio (95% CI) . | Level P value . | Overall P value . |
|---|---|---|---|
| Nonvariant factors | |||
| Age, per 10-y decrease | 1.312 (1.120-1.553) | — | < .001 |
| Male (vs female) | 0.814 (0.466-1.467) | — | .497 |
| Transplant (vs native) | 1.248 (0.518-2.895) | — | .610 |
| Time on Eculizumab prior to d/c (mo) | 1.023 (0.997-1.049) | — | .076 |
| Variant-specific factors | |||
| One or more variants detected (vs none) | 6.100 (3.215-12.466) | — | < .001 |
| Number of variants | — | — | < .001 |
| Single variant (vs none) | 7.060 (3.654-14.644) | < .001 | — |
| Multiple variants (vs none) | 8.333 (2.896-24.685) | < .001 | — |
| CFH-inclusive variant (vs other variants + none) | 4.341 (2.386-7.997) | — | < .001 |
| Type of variant - CFH | — | — | < .001 |
| Non-CFH inclusive variant (vs none) | 4.460 (2.235-9.468) | < .001 | — |
| CFH inclusive variant (vs none) | 10.577 (4.928-24.085) | < .001 | — |
| Variant of greatest pathogenicity | — | < .001 | |
| CFH (vs none) | 10.667 (4.939-24.431) | < .001 | — |
| C3 (vs none) | 9.524 (2.947-32.050) | < .001 | — |
| MCP/CD46 (vs none) | 7.895 (3.326-19.534) | < .001 | — |
| Other/variant not specified (vs none) | 2.355 (0.995-5.629) | .051 | — |
| Variant pathogenicity | — | — | < .001 |
| VUS (vs none) | 4.398 (1.967-10.196) | < .001 | — |
| Pathogenic/likely pathogenic variants (vs none) | 14.683 (6.764-33.991) | < .001 | — |
| . | Odds ratio (95% CI) . | Level P value . | Overall P value . |
|---|---|---|---|
| Nonvariant factors | |||
| Age, per 10-y decrease | 1.312 (1.120-1.553) | — | < .001 |
| Male (vs female) | 0.814 (0.466-1.467) | — | .497 |
| Transplant (vs native) | 1.248 (0.518-2.895) | — | .610 |
| Time on Eculizumab prior to d/c (mo) | 1.023 (0.997-1.049) | — | .076 |
| Variant-specific factors | |||
| One or more variants detected (vs none) | 6.100 (3.215-12.466) | — | < .001 |
| Number of variants | — | — | < .001 |
| Single variant (vs none) | 7.060 (3.654-14.644) | < .001 | — |
| Multiple variants (vs none) | 8.333 (2.896-24.685) | < .001 | — |
| CFH-inclusive variant (vs other variants + none) | 4.341 (2.386-7.997) | — | < .001 |
| Type of variant - CFH | — | — | < .001 |
| Non-CFH inclusive variant (vs none) | 4.460 (2.235-9.468) | < .001 | — |
| CFH inclusive variant (vs none) | 10.577 (4.928-24.085) | < .001 | — |
| Variant of greatest pathogenicity | — | < .001 | |
| CFH (vs none) | 10.667 (4.939-24.431) | < .001 | — |
| C3 (vs none) | 9.524 (2.947-32.050) | < .001 | — |
| MCP/CD46 (vs none) | 7.895 (3.326-19.534) | < .001 | — |
| Other/variant not specified (vs none) | 2.355 (0.995-5.629) | .051 | — |
| Variant pathogenicity | — | — | < .001 |
| VUS (vs none) | 4.398 (1.967-10.196) | < .001 | — |
| Pathogenic/likely pathogenic variants (vs none) | 14.683 (6.764-33.991) | < .001 | — |